

**2017 Spring Meeting of Participants**

**PLENARY SESSION**  
**Friday, April 28, 2017**  
**4:30 – 5:35 pm**

**MOUNTBATTEN BALLROOM**

<b>Time</b>	<b>Topic</b>	<b>Presenter</b>
4:30 – 4:35	WELCOME	Drs Annette Hay / Lois Shepherd
4:35 – 4:45	IND.226 - A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given with or without Standard Chemotherapy Regimens	Dr. Desiree Hao
4:45 – 4:55	CO.23 - A Phase III Randomized Study of BBI608 and Best Supportive Care versus Placebo and Best Supportive Care in Patients with Pretreated Advanced Colorectal Carcinoma	Dr. Derek Jonker
4:55 – 5:05	ALC.3 - A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)	Dr. Lynn Savoie
5:05 – 5:15	Safety Reporting in Clinical Trials	Dr. Scott Laurie
5:15 – 5:25	MA.17R - A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study)	Dr. Wendy Parulekar
5:25 – 5:35	Progress in Breast Cancer	Dr. Kathy Pritchard